16 hours agoNovavax begins the next phase of the vaccine study for Individual-19
Periskopi(6 years ago)
(6 years ago)U.S. drug developer Novavax said during the day that he started the middle stage of his research on the vivid-19 experimental vaccine in South Africa, while the West is experiencing an increase in coronary cases. Testing studies of NNCX-CoV2373 will be held at two thousand and 665 adults and [...]
Testing studies of NNCX-CoV2373 will be held at two thousand and 665 healthy adults and will assess their security and immunogenity.
Because South Africa is experiencing a winter wave of Covid-19, this important clinical testing has the potential to offer an early inefficiency indicator,” said Novavax Research Chief Gregory Glenn, Reuters reports.
South Africa is the fifth most hit country in the world with 583 thousand and 653 cases of coronary and 11 thousand and 667 dead so far.
In July, the US government has granted Novavax $1.6 billion to cover the testing and manufacturing of the potential vaccine for the new choreography in the United States with the aim of creating 100 million doses by January. /Periscope
